Laboratorio de Errores Innatos del Metabolismo y Tamiz, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de Mexico 04530, Mexico.
Laboratorio de Biología Molecular, Subdirección de Investigación Médica, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de Mexico 04530, Mexico.
Genes (Basel). 2021 Oct 23;12(11):1676. doi: 10.3390/genes12111676.
Establishing the genotypes of patients with hyperphenylalaninemia (HPA)/phenylketonuria (PKU, MIM#261600) has been considered a cornerstone for rational medical management. However, knowledge of the phenylalanine hydroxylase gene ( mutational spectrum in Latin American populations is still limited. Herein, we aim to update the mutational spectrum in the largest cohort of HPA/PKU Mexican patients ( = 124) reported to date. The biallelic genotype was investigated by Sanger automated sequencing, and genotypes were correlated with documented biochemical phenotypes and theoretical tetrahydrobiopterin (BH) responsiveness. Patients were biochemically classified as having classic PKU (50%, 62/124), mild PKU (20.2%, 25/124) and mild HPA (29.8%, 37/124). Furthermore, 78.2% of the included patients (97/124) were identified by newborn screening. A total of 60 different pathogenic variants were identified, including three novel ones (c. 23del, c. 625_626insC and c. 1315 + 5_1315 + 6insGTGTAACAG), the main categories being missense changes (58%, 35/60) and those affecting the catalytic domain (56.6%, 34/60), and c. 60 + 5G > T was the most frequent variant (14.5%, 36/248) mainly restricted (69.2%) to patients from the central and western parts of Mexico. These 60 types of variants constituted 100 different biallelic PAH genotypes, with the predominance of compound-heterozygous ones (96/124, 77%). The expected BH responsiveness based on the genotype was estimated in 52% of patients (65/124), mainly due to the p. (Val388Met) (rs62516101) allele. Instead, our study identified 27 null variants with an allelic phenotype value of zero, with a predominance of c. 60 + 5G > T, which predicts the absence of BH responsiveness. An identical genotype reported in BIOPKUdb was found in 92/124 (74%) of our patients, leading to a genotype-phenotype concordance in 80/92 (86.9%) of them. The high number of variants found confirms the heterogeneous and complex mutational landscape of HPA/PKU in Mexico.
确定高苯丙氨酸血症(HPA)/苯丙酮尿症(PKU,MIM#261600)患者的基因型一直被认为是合理医疗管理的基石。然而,拉丁美洲人群苯丙氨酸羟化酶基因( mutational spectrum 的知识仍然有限。在此,我们旨在更新迄今为止报道的最大的 HPA/PKU 墨西哥患者队列( = 124)的突变谱。通过 Sanger 自动化测序研究双等位基因基因型,并将基因型与文献记载的生化表型和理论四氢生物蝶呤(BH)反应性相关联。患者的生化分类为经典 PKU(50%,62/124)、轻度 PKU(20.2%,25/124)和轻度 HPA(29.8%,37/124)。此外,包括的患者中有 78.2%(97/124)通过新生儿筛查确定。共鉴定出 60 种不同的致病性变异,包括三种新变异(c.23del、c.625_626insC 和 c.1315 + 5_1315 + 6insGTGTAACAG),主要类别为错义变化(58%,35/60)和影响催化结构域的变化(56.6%,34/60),c.60 + 5G > T 是最常见的变异(14.5%,36/248),主要局限于(69.2%)来自墨西哥中部和西部的患者。这 60 种变异构成了 100 种不同的双等位基因 PAH 基因型,以复合杂合子为主(96/124,77%)。根据基因型估计 BH 反应性的预期在 52%的患者(65/124)中,主要归因于 p.(Val388Met)(rs62516101)等位基因。相反,我们的研究鉴定了 27 种具有等位基因表型值为零的无效变异,以 c.60 + 5G > T 为主,这预示着缺乏 BH 反应性。我们的患者中有 92/124(74%)报告了 BIOPKUdb 中相同的基因型,导致其中 80/92(86.9%)的基因型与表型一致。发现的大量变异证实了墨西哥 HPA/PKU 的异质性和复杂突变谱。